Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280728 | 0.85 | SYK (0.78) | SYK | |
| SCHEMBL27981775 | 0.84 | SYK (0.52) | SYKTP53MAPT | |
| SCHEMBL3654933 | 0.81 | SYK (0.71) | SYK | |
| SCHEMBL589047 | 0.80 | SYK (1.00) | SYK | |
| SCHEMBL5318610 | 0.80 | KDM4E (0.46) | SYKTP53MAPT | |
| SCHEMBL3281404 | 0.79 | SYK (0.75) | SYK | |
| SCHEMBL3284987 | 0.78 | SYK (0.74) | SYK | |
| SCHEMBL588879 | 0.76 | SYK (1.00) | SYK | |
| SCHEMBL373919 | 0.76 | SYK (0.61) | SYK | |
| SCHEMBL3280742 | 0.76 | KDM4E (0.53) | TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824828-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | Peakdale Molecular Limited (GB) | 2007-08-29 | — | — | EP | claimed |
| WO-2006059103-A2 | PYRIDINE BASED COMPOUNDS USEFUL AS INTERMEDIATES FOR PHARMACEUTICAL OR AGRICULTURAL END-PRODUCTS | PEAKDALE MOLECULAR LIMITED (GB) | 2006-06-08 | — | — | WO | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| US-7321041-B2 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321041-B2 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003057695-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | SYK 1/4885TP53 2773/4885MAPT 4318/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885TP53 4503/4885MAPT 4883/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | SYK 466/4885TP53 1517/4885MAPT 4255/4885 |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | SYK, IRAK1, IRAK3 | SYK 1/4885TP53 2783/4885MAPT 4471/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885TP53 4503/4885MAPT 4883/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885TP53 4503/4885MAPT 4883/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | SYK 1864/4885TP53 1961/4885MAPT 4872/4885 |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | SYK 1/4885TP53 2773/4885MAPT 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.